#1 Clinical Trials Search in Europe

Ceralasertib

Ceralasertib, also known as AZD6738, is an innovative drug currently being investigated in various clinical trials for its potential in treating different types of cancer. This article explores the ongoing research into Ceralasertib’s efficacy, safety, and potential applications in cancer therapy, particularly in combination with other treatments.

Table of Contents

What is Ceralasertib?

Ceralasertib, also known as AZD6738, is an experimental anti-cancer drug that is currently being studied in various clinical trials[1]. It belongs to a class of medications called ATR inhibitors, which target a specific protein in cancer cells[2]. Ceralasertib is taken orally, usually in the form of tablets[1].

How Ceralasertib Works

Ceralasertib works by inhibiting a protein called ATR (Ataxia Telangiectasia and Rad3-related protein). This protein plays a crucial role in helping cancer cells repair their DNA when it’s damaged. By blocking ATR, ceralasertib makes it harder for cancer cells to survive and grow[3]. This mechanism is particularly interesting because it targets a vulnerability specific to cancer cells, potentially making the treatment more effective and less harmful to healthy cells.

Types of Cancer Treated with Ceralasertib

Ceralasertib is being studied for use in various types of cancer, including:

  • Advanced solid tumors: This includes a wide range of cancers that form solid masses[1]
  • Non-small cell lung cancer (NSCLC): A common type of lung cancer[4]
  • Melanoma: A type of skin cancer[5]
  • Head and neck squamous cell carcinoma (HNSCC): Cancers that begin in the cells that line the mouth, nose, and throat[3]
  • Chronic lymphocytic leukemia (CLL): A type of blood cancer[2]
  • Renal cell carcinoma: A type of kidney cancer[6]
  • Pancreatic cancer[6]
  • Endometrial cancer: Cancer of the uterus lining[6]
  • Prostate cancer[6]
  • Osteosarcoma: A type of bone cancer[7]

Clinical Trials Involving Ceralasertib

Ceralasertib is currently being studied in various clinical trials to determine its effectiveness and safety. These trials are testing the drug alone and in combination with other treatments. Some key points about these trials include:

  • Phase 1 and 2 trials are being conducted to assess the safety, proper dosing, and initial effectiveness of ceralasertib[1][5]
  • Researchers are studying how well ceralasertib works in patients whose cancer has returned or not responded to previous treatments[4]
  • Some trials are looking at biomarkers (specific molecules or genes) that might help predict which patients will respond best to ceralasertib[3]
  • The effectiveness of ceralasertib is being measured by factors such as tumor shrinkage, how long patients live without their cancer getting worse, and overall survival[4]

Combination Therapies with Ceralasertib

Ceralasertib is being studied both as a standalone treatment and in combination with other cancer drugs. Some notable combinations include:

  • Ceralasertib + Durvalumab: Durvalumab is an immunotherapy drug that helps the immune system fight cancer. This combination is being tested in lung cancer and other solid tumors[4][8]
  • Ceralasertib + Olaparib: Olaparib is another targeted therapy that works on DNA repair in cancer cells. This combination is being studied in various solid tumors[6]
  • Ceralasertib + Acalabrutinib: This combination is being tested in chronic lymphocytic leukemia[2]

Potential Side Effects

As with all medications, ceralasertib may cause side effects. While the full range of side effects is still being studied, some potential effects observed in clinical trials include:

  • Changes in blood cell counts, which could increase the risk of infection or bleeding[1]
  • Fatigue or tiredness[3]
  • Nausea or vomiting[3]
  • Changes in liver function tests[3]

It’s important to note that side effects can vary from person to person, and not everyone will experience all or any of these effects. Patients in clinical trials are closely monitored for any adverse reactions.

Future Prospects

Ceralasertib shows promise in the treatment of various types of cancer, particularly those that have not responded to other treatments. Ongoing research aims to:

  • Determine which patients are most likely to benefit from ceralasertib[3]
  • Explore the most effective combinations of ceralasertib with other cancer treatments[4]
  • Understand how ceralasertib affects the immune system’s response to cancer[3]
  • Evaluate the long-term effectiveness and safety of ceralasertib[4]

While ceralasertib is still an experimental drug, the ongoing clinical trials offer hope for new treatment options for patients with various types of cancer, especially those who have not responded to current therapies.

Aspect Details
Drug Name Ceralasertib (AZD6738)
Mechanism of Action ATR inhibitor (DNA damage response agent)
Administration Oral tablets
Cancer Types Studied Advanced solid tumors, NSCLC, melanoma, osteosarcoma, CLL
Combination Therapies Durvalumab, olaparib, acalabrutinib
Key Outcomes Measured Safety, tolerability, pharmacokinetics, objective response rate, progression-free survival, overall survival
Trial Phases Phase 1, Phase 2, Phase 3
Notable Features Being studied in patients with resistance to prior therapies, exploring potential in immunotherapy combinations

FAQ

  • What is Ceralasertib? Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR (Ataxia Telangiectasia and Rad3-related protein). It is being studied as a potential treatment for various types of cancer.
  • What types of cancer is Ceralasertib being tested for? Ceralasertib is being investigated for several cancer types, including advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, osteosarcoma, and chronic lymphocytic leukemia (CLL).
  • How is Ceralasertib administered? Ceralasertib is typically administered orally in the form of tablets. The dosage and frequency may vary depending on the specific clinical trial and treatment regimen.
  • Is Ceralasertib being studied alone or in combination with other drugs? Ceralasertib is being studied both as a monotherapy and in combination with other drugs. Common combinations include Ceralasertib with durvalumab (an immunotherapy drug) and Ceralasertib with olaparib (a PARP inhibitor).
  • What are the potential side effects of Ceralasertib? As with any investigational drug, the full range of side effects is still being studied. Clinical trials are monitoring for adverse events, which may include changes in blood cell counts, fatigue, and other symptoms. The safety profile is being carefully evaluated in each trial.

Ongoing Clinical Trials on Ceralasertib

  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Hungary Ireland Italy +4

  • Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Spain

  • Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Spain

  • Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of Ceralasertib for Patients with Advanced Cancer with Molecular Changes

    Not recruiting

    1 1
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Olaparib, Ceralasertib, and AZD1775 for Patients with Metastatic Triple Negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland Portugal Spain

  • Study on Ceralasertib, Oleclumab, and Monalizumab for Advanced Non-Small Cell Lung Cancer Patients Resistant to PD-1 Inhibitors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • ATR: ATR stands for Ataxia Telangiectasia and Rad3-related protein. It is a protein kinase that plays a crucial role in DNA damage response and cell cycle regulation.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1. It is a set of rules used to assess how well a cancer patient responds to treatment by measuring the size of tumors.
  • PD-(L)1: Programmed Death-1 (or its ligand). It refers to a protein found on immune cells that acts as a checkpoint to regulate the immune system.
  • Durvalumab: An immunotherapy drug that works by blocking the interaction of PD-L1 with PD-1, potentially enhancing the immune system's ability to attack cancer cells.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose during a clinical trial.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Biomarker: A measurable indicator of a biological state or condition, often used to determine the presence or progression of a disease or the effects of treatment.

References

  1. https://clinicaltrials.gov/study/NCT05469919
  2. https://clinicaltrials.gov/study/NCT03328273
  3. https://clinicaltrials.gov/study/NCT03022409
  4. https://clinicaltrials.eu/trial/study-comparing-ceralasertib-and-durvalumab-with-docetaxel-for-patients-with-advanced-non-small-cell-lung-cancer-after-previous-treatments/
  5. https://clinicaltrials.eu/trial/study-on-ceralasertib-and-durvalumab-for-patients-with-advanced-melanoma-resistant-to-pd-l1-therapy/
  6. https://clinicaltrials.gov/study/NCT03682289
  7. https://clinicaltrials.gov/study/NCT04417062
  8. https://clinicaltrials.gov/study/NCT05514132